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While clearly different in their aims and means, classification and diagnosis both try to accur-
ately label the disease patients are suffering from. For systemic lupus erythematosus (SLE),
this is complicated by the multi-organ nature of the disease and by our incomplete under-
standing of its pathophysiology. Hallmarks of SLE are the presence of antinuclear antibodies
(ANA), and multiple immune-mediated organ symptoms that are largely independent. In an
attempt to overcome limitations of the current sets of SLE classification criteria, a new four-
phase approach is being developed, which is jointly supported by the European League
Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). This
review attempts to delineate the performance of the current sets of criteria, the reasons for the
decision for classification, and not diagnostic, criteria, and to provide a background of the
current approach taken. Lupus (2016) 25, 805–811.
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Introduction
Deﬁning systemic lupus erythematosus (SLE), both
in classiﬁcation and in clinical diagnosis, has
remained one of the challenging questions in
Rheumatology. After all, the very nature of this
condition is not fully understood. SLE will often
be the underlying condition when patients present
with either a combination of fever, lymphadenop-
athy, malar rash and polyserositis, or with immune
complex glomerulonephritis, but may also present
as new-onset polyarthritis or another organ-speciﬁc
manifestation with no other obvious symptoms.
Therefore, some experts view SLE as a syndrome
rather than a single disease. Dividing SLE into sep-
arate entities in such a way, however, might mean
assigning speciﬁc phenotypes to very small groups
of patients, or even to single patients. Abolishing
the common idea of one disease would help neither
our understanding of the pathophysiology of the
disease, nor clinical decision making today. In our
view, there are suﬃcient similarities to keep the
faces of SLE together, and we favor the standpoint
of seeing SLE as one disease.
It is of course evident that SLE can have literally
hundreds of manifestations related to autoimmun-
ity, which possibly are independent of each other.
In addition to cellular immune activation, it is the
hallmark of the disease that these manifestations
are due to various antibodies and often to
immune complexes consisting of autoantigen and
autoantibodies. In fact, essentially all inﬂammatory
manifestations of SLE are associated with immune
complexes, while cytopenias and some nervous
system symptoms are probably initiated by the
direct eﬀects of autoantibody binding.1,2 For
many organ manifestations, the autoantibody spe-
ciﬁcities at fault are not fully known. However, in
the worldwide routine setting, there are still more
than a dozen autoantibodies3 that are being mea-
sured and are associated with SLE at diﬀerent
degrees of sensitivity and speciﬁcity (Table 1).
Most of the autoantibodies measured in clinical
practice for SLE assessment are directed against
nuclear antigens. The complete absence of
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antinuclear antibodies (ANA) is, in fact, a rather
uncommon situation in patients whom most SLE
experts would ﬁnd to have SLE,4–6 and roughly
half of all SLE patients have antibodies to
double-stranded DNA (dsDNA), at least in epi-
sodes of disease activity.7 Antibodies to dsDNA,
but also those to RNA, achieve binding to the
nuclear acids via diﬀerences in charge. This import-
ant biophysical characteristic, presumably in an
indirect way via histone binding,8 also explains
their aﬃnity to basal membranes. It appears some-
what uncertain whether the propensity to form
such antibodies truly is an inherent feature of the
disease, or whether the immune system is simply
more prone to developing such antibodies based
on the MHC association than autoantibodies to
other antigens.
Even more than the propensity to develop
ANA, the development of multiple autoantibodies
is the cardinal feature of SLE.9,10 In fact, it appears
that the development of SLE is associated not only
with the new occurrence of autoantibodies typical
of SLE, but also with the development of antibo-
dies associated with organ-speciﬁc autoimmunity,
such as autoimmune thyroiditis.9,10 The distinction
between organ-speciﬁc and systemic autoimmunity
is still underexplored and imprecise. Since we
commonly limit testing to well-deﬁned autoantibo-
dies, the known antibody ﬁndings only constitute
a part of the whole picture. Many other
autoantibodies may be present. It is still unclear
whether there are common or numerous distinct
mechanisms that underlie this dangerous main fea-
ture of the disease.
SLE classification—the ACR and
the SLICC criteria
To a signiﬁcant degree, both the 1982 (and
revised 1997) American College of Rheumatology
(ACR) and the 2012 Systemic Lupus International
Cooperating Clinics (SLICC) sets of classiﬁcation
criteria depict the above-sketched picture of the
prototypical multi-organ systemic autoimmune dis-
ease.4,5,11 These criteria mostly list organ manifest-
ations that are likely antibody and/or immune
complex mediated in this setting.
Being among the ﬁrst sets of criteria derived with
modern technology, the 1982 (and revised 1997)
ACR criteria have shaped the concept of SLE of
most of the physicians practicing today. In fact,
most physicians will have learned them by heart.
This very fact, however, also represents a point
of criticism. One of the reasons for learning the
criteria by heart was that they are not entirely intui-
tive. Nevertheless, they have worked well for clin-
ical and various other studies, and have often even
been (inadequately) used for diagnostic purposes.
Over time, new features of SLE have been
described, such as subacute cutaneous LE, and it
has been debated whether all of the cutaneous and
mucocutaneous features—such as UV sensitivity,
oral ulcers and skin lesions—are indeed independ-
ent, or represent manifestations of the same SLE
manifestation.12 While speciﬁcity was usually con-
sidered satisfactory, the sensitivity of the ACR cri-
teria has been seen as suboptimal, in new-onset and
childhood SLE in particular.13 Moreover, the 1997
revision was never formally tested. The latter has
changed through a substantial eﬀort by the SLICC
group to devise new SLE criteria. In this process
the SLICC investigators also validated the 1997
criteria, and found a sensitivity of 83% and a spe-
ciﬁcity of 96%.5 The SLICC group have made a
number of a priori choices that have shaped their
set of criteria. Primarily, they decided that the
structure of the criteria should stay the same. In
consequence, four features are still needed for
SLE classiﬁcation, and the features have not been
weighted. However, there is one important excep-
tion: biopsy-proven lupus nephritis was declared to
suﬃciently classify the disease when in combination
with ANA or anti-dsDNA antibodies. The SLICC
investigators also chose to better depict the role of
autoimmunity. This resulted in the deﬁnition that
Table 1 Autoantibodies in SLE diagnosis and classification.
Autoantibody test
Sensitivity estimate
(based on
refs 2–6, 23)
Specificity
for SLE? Other diseases
ANA (HEp-2 IFLU) 98 No Many
Anti-dsDNA 50 Yes (95%) –
Anti-Histone 50 No DIL, SSc, JIA
Anti-C1q 30 No IC vasculitidesa
Anti-Sm 10 Yes (99%) –
Anti-Ro60 40 No Sjo¨gren’s,
CLEa, SSc
Anti-SSB/La 20 No Sjo¨gren’s
Anti-U1RNP 20 No MCTD
Rheumatoid factors 20 No RA, Sjo¨gren’s
Anti-Cardiolipin IgG 20 Noa Primary APSa
Anti-Cardiolipin IgM 10 Noa Primary APSa
Lupus anticoagulant 10 Noa Primary APSa
aThe differential diagnoses can also be part of the SLE spectrum.
IFLU: immunofluorescence; DIL: drug-induced lupus; SSc: systemic
sclerosis; JIA: juvenile idiopathic arthritis; IC: immune complex; CLE:
cutaneous lupus erythematosus; MCTD: mixed connective tissue dis-
ease; RA: rheumatoid arthritis; APS: anti-phospholipid (Hughes’)
syndrome.
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classiﬁcation demands at least one immunological
and at least one clinical criterion being fulﬁlled.
While both the decisions on biopsy-proven lupus
nephritis and on the necessity to have at least one
immunological criterion make intuitive sense, it is a
fact that these were more eminence based than data
driven. The other choice that was not entirely based
on data is the inclusion of a full textbook list of all
possible forms of acute, subacute, and chronic cuta-
neous LE, which were subsequently tested together
under these combined headings. Accordingly, there
are no data on the performance of rather unusual
entities such as lupus tumidus, which is also rarely
associated with SLE.14–16 Similarly, the list of
neuropsychiatric symptoms was expanded, and
some of the other deﬁnitions were slightly modiﬁed.
The SLICC group deﬁned improved sensitivity
as a major goal, and their SLE criteria have
indeed clearly surpassed the 1997 ACR criteria
in this regard. Several groups have compared
the two sets, and there is complete agreement
that the SLICC criteria are more sensitive.13,17–20
The SLICC criteria sensitivity has been found in
the range between 92% and 97%, whereas the
1997 ACR criteria had 77% to 91% sensitivity.
However, and not entirely unexpectedly given the
similar structure, speciﬁcity dropped from 91–96%
for the 1997 ACR criteria to 74–88% for the
SLICC criteria. It is therefore not clear which set
of criteria is more useful, and there is some result-
ing uncertainty and local diﬀerence in the preferred
set. Having only one set would, in the longer term,
be clearly preferable, but for trial purposes either of
the two is acceptable to the Food and Drug
Administration and European Medicines Agency
regulatory agencies.
Differences between diagnosis and classification
As compared with classiﬁcation by criteria, clinical
diagnosis is actually quite diﬀerent. Diagnosis and
classiﬁcation both aim at accurately deciding
whether the underlying disease in an individual
patient is or is not SLE. However, the purposes
diﬀer, and so do the means (Table 2).21 While clas-
siﬁcation mainly deﬁnes a rather homogenous set
of patients for research purposes, diagnosis focuses
on the individual patient’s prognosis and therapy.
In consequence, suboptimal sensitivity in diagnosis
can be a very serious problem. With 95% sensitiv-
ity, 1 in 20 true SLE patients would still be missed
and not given appropriate treatment. This is one of
the most relevant arguments against diagnostic
criteria. Not meeting the diagnostic criteria would
endanger these patients, if in need of expensive
therapies in particular. This is one of the major
arguments why neither ACR nor EULAR are will-
ing to back diagnostic criteria.21 Low speciﬁcity
may also have an impact on health care cost, in
part caused by additional testing.22 However, the
diagnosis of SLE in itself, without any proof of
relevant organ disease, should therapeutically lead
to the use of hydroxychloroquine (and perhaps
vitamin D) only. Basing more therapeutic steps
on the SLE diagnosis would be a signiﬁcant
misconception.
On the other hand, criteria will only be useful if
practicable. Optimally, they are easily learned by
heart, or printed on one single page. In contrast,
in making a diagnosis the conventional way, the
treating physician will be able to take any piece of
information into account. A family history of auto-
immunity, or rather unspeciﬁc features such as
arthralgias, myalgias, or fatigue, may tip the bal-
ance towards the diagnosis. Additional informa-
tion, such as old laboratory reports that showed
leukocytopenia long before disease onset, may
lead to discounting certain features. It is important
in this regard that diagnosis is seen as an ongoing
and reiterative process. Physicians should re-ques-
tion their diagnosis whenever the course of disease
does not ﬁt expectations.
The latter would have dramatic consequences in
classiﬁcation. A patient fulﬁlling classiﬁcation cri-
teria for SLE, who would accordingly be included
into a randomized therapeutic trial, cannot be
simply withdrawn by post hoc change of classiﬁca-
tion. Speciﬁcity thus is a critical issue in classiﬁca-
tion. In contrast, for classiﬁcation purposes, 90%
sensitivity would allow for inclusion of most
patients, and the 10% missed will usually not
make a dramatic diﬀerence. Therefore, fundamen-
tally diﬀerent from diagnosis, sensitivity is not so
Table 2 Differences between diagnosis and classification.
Diagnosis Classification
Aim Individual prognosis and
therapy.
Homogenous groups for
research purposes.
Information
base
Theoretically unlimited
information of various
natures and sources.
Feasible, and therefore
limited set of objective
criteria only.
Sensitivity Critical issue (will often
limit access to therapy).
Low sensitivity narrows
patient population, but
is usually not critical.
Specificity Diagnosis will be ques-
tioned if new informa-
tion sheds doubt.
Critical issue (starting
point classification
cannot be corrected).
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critical in classiﬁcation. These diﬀerences are also
shown in Table 2.
SLE diagnosis
It is, therefore, evident why neither the ACR nor
the SLICC classiﬁcation criteria for SLE should be
directly used for diagnostic purposes. Even the best
sensitivity and speciﬁcity values of these sets show
that at least 4% of patients would incorrectly be
given, or not given, the diagnosis. Nevertheless,
these criteria shape our understanding of SLE.
They provide a framework to model our diagnostic
process on; this process will eventually go much
further. What is it, then, that will indicate a diag-
nosis of SLE? Looking at the two sets of criteria,
they mainly depict multiple autoimmune features
that together form the disease. Some of these fea-
tures are quite speciﬁc, such as immune complex
glomerulonephritis or autoantibodies to the Smith
(Sm) antigen.4,5 Others may be relatively speciﬁc
given the right test and/or the right circumstances,
such as anti-dsDNA antibodies or pleuritis in the
absence of infection and pulmonary embolism. Still
others, including positive ANA or arthritis, are in
fact quite unspeciﬁc.5,23
Under these circumstances, diﬀerential diagnoses
are an important aspect of the diagnostic work-up.
These include infections (viral infections, in particu-
lar), hematological disease, and a wide variety of
autoimmune diseases. The latter include entities
clearly distinct from SLE, such as Hashimoto’s thyr-
oiditis, rheumatoid arthritis or primary Sjo¨gren’s
syndrome, but also such that can occur both as enti-
ties on their own or as part of the SLE spectrum, for
example anti-phospholipid syndrome, autoimmune
hemolytic anemia, or cutaneous LE.
The challenge is to screen the patient’s symptoms
and results for those SLE-compatible symptoms
most probably induced by immune complexes, or
by speciﬁc autoantibodies (IgG type). Complement
consumption, usually measured as decreased C3c
and/or C4, is evidence for immune complex disease.
Two or more independent antibody-mediated or
immune complex-mediated features that are com-
patible with SLE will usually make the diagnosis
likely. However, there are situations that make a
ﬁrm diagnosis diﬃcult. A prominent example is
bacterial endocarditis, which often leads to
immune complex disease,24 and may be accompa-
nied by various immune phenomena.
If there is clinical suspicion of SLE, ANA usually
is a good screening test with high sensitivity.
Nevertheless, if there is substantial evidence for
the disease, testing for anti-dsDNA antibodies
and antibodies to extractable nuclear antigens
(ENA) is recommended in addition.25,26 This is
mainly based on ﬁndings that anti-Ro60 and cer-
tain other SLE-related autoantibodies may be
missed by ANA testing using HEp-2 cells.27 In
our opinion, ANA (or ENA or anti-dsDNA anti-
bodies) plus at least two independent SLE organ
symptoms not otherwise explained, or one such
symptom and an independent antibody, usually
make the diagnosis quite likely. For example, arth-
ritis in the absence of anti-CCP antibodies, but with
positive ANA and positive anti-dsDNA antibodies
(detected by a speciﬁc test) will be diagnosed as
SLE, unless there is an acute infection known to
often elicit autoantibodies. It is interesting that a
similar approach was independently used in
Sweden.19 It is obvious that more speciﬁc symp-
toms will be given more weight in the diagnostic
process. Anti-dsDNA antibodies in the absence of
ANA should be regarded with great caution, since
this situation means that one result must be clinic-
ally wrong. Nevertheless, and without any fault on
the part of the laboratory, such situations occasion-
ally occur.
In most instances, this is a fairly straightforward
approach, but it may, for example, be challenging to
decide between infection plus SLE and infection
alone. There are two important caveats. In our opin-
ion, nobody should receive a diagnosis of SLE if
there are no disease symptoms. Autoantibody com-
binations may eventually be found to predict future
disease,28,29 and this might then invite early thera-
peutic measures in the future, but there is no disease
without symptoms. The other aspect is that a diag-
nosis of SLE in itself calls for hydroxychloroquine,
and probably vitamin D and sun protection, but
neither necessitates glucocorticoids or immunosup-
pressive agents, nor does it impact on who best cares
for an individual patient. In the latter regard, two
diﬀerent, independent LE skin manifestations in the
presence of ANA will usually mean underlying SLE,
but the patient will still be best cared for by a
dermatologist.
A process towards new classification criteria
In full awareness of the diﬀerences between diagno-
sis and classiﬁcation of SLE,21 would it not still be
helpful to get closer to the diagnostic process with
classiﬁcation criteria? A feasible set of classiﬁcation
criteria will still not make for a diagnostic tool, but
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parallel ways of reasoning for classiﬁcation and
diagnosis would make life easier. Therefore, we
have embarked on a large SLE criteria project,
which is jointly supported by the EULAR and the
ACR, and accordingly guided by a steering com-
mittee of 12 members. The aim is to develop clas-
siﬁcation criteria with speciﬁcity comparable with
the ACR 1997 criteria, but with improved sensitiv-
ity, in early disease in particular.30 In addition, we
would like to arrive at a more intuitive approach
that is easier to learn. It is important that the cri-
teria approach rigorously keeps to scientiﬁc meth-
ods, and that circular reasoning is avoided.31–34
In order to achieve this, a four-phase process was
developed. In phase I, publications on ANA sensi-
tivity and speciﬁcity were collected in a systematic
literature review.6,35 This was based on the idea
that in a patient with clinical suspicion of SLE,
such as in a young female patient with otherwise
unexplained myalgias and fatigue, the next step in
diagnosis would be to test for ANA. Likewise, for
classiﬁcation criteria, the performance characteris-
tics of ANA would better ﬁt the description of an
entry criterion. HEp2 ANA immunoﬂuorescence
data of 10,089 SLE patients was included, and ana-
lyzed by meta-regression. At a titer of 1:80, a sen-
sitivity of 98.1% was calculated, with a
corresponding speciﬁcity of 83.3%. At 1:160, sen-
sitivity was 95.4%. Accordingly, ANA of at least
1:80 may indeed represent a useful entry criterion.
Additional tests, for example for antibodies against
DSF-70, which almost exclude SLE, could improve
ANA speciﬁcity,36 but they are not (yet) available
worldwide. In the remainder of the ﬁrst phase, the
focus has been item generation, based on three dif-
ferent approaches. First, a large international
expert Delphi exercise resulted in a list and rating
of criteria that should be considered for SLE classi-
ﬁcation for adults as well as for children.37 Second,
in an international, multiethnic, adult early SLE
patient cohort, ﬁndings in patients with SLE were
compared with those of patients with mimicking
conditions.38,39 Third, patient members of the
German lupus patient association were approached
via their quarterly magazine ‘‘Schmetterling’’
(butterﬂy), and asked to anonymously ﬁll in and
mail a paper survey on symptoms they had around
the onset of their disease. More than 300 patients
responded.40 The inclusion of the patient perspective
has not historically been done in criteria develop-
ment, and is a novel aspect of this work.
In the second phase, item reduction was done in
a nominal group technique exercise with the steer-
ing committee and a group of high-proﬁle SLE
experts from both North America and Europe
who were not members of the steering committee.
The expert panel distinguished potential ‘‘entry cri-
teria’’, which would be required for classiﬁcation,
from other potential ‘‘additive criteria.’’ Redundant
or poorly performing criteria were removed. An
abstract reporting the results has been submitted to
the 2016 EULAR congress in London. Since there
has been a suggestion that criteria cluster into clinic-
ally sensible domains or ‘‘buckets’’, it is currently
being evaluated whether single features are independ-
ent of each other. This is done both in a literature
review and using the data of the early patient inter-
national cohort. With this information, the items will
be weighted in Phase 3, using multicriteria decision
analysis,41,42 as was done for the ACR/EULAR
rheumatoid arthritis and systemic sclerosis classiﬁca-
tion criteria.43–46 Finally, in Phase 4, the newly
derived candidate criteria will be tested in large inde-
pendent patient cohorts, and against both the 1997
ACR and the 2012 SLICC criteria.
Conclusions
In part because the medicolegal implications of not
meeting diagnostic criteria for SLE in an SLE
patient would convey risks, there is consensus
that diagnostic criteria will not be backed by
either EULAR or ACR. In contrast, classiﬁcation
criteria not only shape our understanding of the
disease, but also serve as a useful backbone for
the diagnostic approach in an individual patient.
Thus, further improving the classiﬁcation criteria
appears worthwhile. The challenge to classify a
highly variable disease such as SLE, which is char-
acterized by a tendency to develop multiple auto-
antibodies, has not changed since the 1982 ACR
criteria. While some clinical advances, including
the deﬁnition of additional forms of cutaneous
lupus and several newly described autoantibodies,
have enriched the ﬁeld, most of the more common
features were known already in 1982. Given the
high quality of the available sets of criteria, which
slightly diﬀer in sensitivity and speciﬁcity, devising
new classiﬁcation criteria for SLE is a considerable
challenge. In a large, collaborative transatlantic
project, we hope to meet this challenge. At least,
in a scientiﬁcally rigorous approach, a robust set of
criteria should be formed and validated, all of
which will be based on a strong rationale. The pro-
ject is intended to be fully inclusive, and everybody
who wants to take part is invited to contact all or
any of the authors. Hopefully, 2017 will bring us
back to uniformly accepted criteria.
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